Generic Name and Formulations:
Lisinopril 2.5mg, 5mg+, 10mg, 20mg, 30mg, 40mg; tabs; +scored.

Company:
AstraZeneca Pharmaceuticals
Indications for ZESTRIL:
To reduce signs/symptoms of systolic heart failure. Adjunct to other therapies within 24hrs post-MI in hemodynamically stable patients, to reduce mortality.

Adult:
HF with diuretic +/or digitalis: initially 5mg once daily; max 40mg once daily; hyponatremia, CrCl ≤30mL/min, or hemodialyis: initially 2.5mg once daily; supervise closely. Reduce diuretic dosage before 1st dose (if possible) and observe until BP is stabilized. Post-MI: 5mg within 24hrs of onset of symptoms, then 5mg after 24hrs, then 10mg after 48hrs, then 10mg once daily for up to 6 weeks; if systolic BP ≤120mmHg at onset, start with 2.5mg daily for 3 days; or if systolic BP ≤100mmHg, start with 5mg daily, then reduce to 2.5mg daily as needed; discontinue if prolonged hypotension (systolic BP ≤90mmHg for >1hr) occurs.

Children:
Not established.

Contraindications:
History of ACEI-associated or other angioedema. Concomitant aliskiren in patients with diabetes.

Warnings/Precautions:
Fetal toxicity may develop; discontinue if pregnancy is detected. Renal impairment. Dialysis (esp. high-flux membrane). Salt/volume depletion. Hypertrophic cardiomyopathy. Severe CHF. Ischemic heart disease. Cerebrovascular disease. Hyponatremia. Renal artery stenosis. Surgery. Monitor BP, electrolytes, renal and liver function. Monitor serum potassium in diabetics. Discontinue if angioedema or laryngeal edema, jaundice or marked elevations of liver enzymes occur. Black patients may have higher rate of angioedema than non-Black patients. Elderly. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.

Interactions:
See Contraindications. May cause hypotension or increased BUN with diuretics. May cause hyperkalemia with K+ sparing diuretics, K+ supplements, or K+-containing salt substitutes. Risk of hypoglycemia with concomitant antidiabetic agents; adjust doses. May be antagonized by, and renal toxicity potentiated by NSAIDs (including COX-2 inhibitors): monitor renal function in elderly and/or volume-depleted. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in diabetics or renal impairment (GFR <60mL/min): not recommended. May increase lithium levels; monitor frequently. Increased risk of angioedema with concomitant mTOR inhibitor (eg, temsirolimus, sirolimus, everolimus). Nitritoid reactions with concomitant injectable gold (eg, sodium aurothiomalate); rare.

Pharmacological Class:
ACE inhibitor.

Adverse Reactions:
Headache, dizziness, cough, hypotension, chest pain, hyperkalemia; renal impairment, angioedema, liver dysfunction, blood dyscrasias (rare).

Elimination:
Renal.

Generic Availability:
YES

How Supplied:
Tabs—100